NASH Commented Articles 2025 - Page 28 Of 42

Patients with biopsy proven NAFLD: a significantly increased cancer incidence

Recent studies link NAFLD to an increased incidence of hepatocellular carcinoma (HCC) and extrahepatic cancers. However, prior studies were small or lacked liver histology, which remains the gold standard for staging NAFLD severity. TG Simon et al...

ByDr. D. Beard
OnMay 27, 2021

Management Articles Commented Articles NASH Observatory Ppar Articles

Fibrosis in NASH: targeted therapies

Progress in uncovering pathogenic determinants of fibrosis in NASH include metabolic dysregulation in hepatocytes that induce inflammation and cytokine secretion leading to cell injury and apoptosis, among others.This review by T. M. Huisman et al. (Division of Liver Diseases, Icahn School of Medicine at Mount Sinai...

ByDr. G. Bozet, MD
OnMay 25, 2021

NASH Observatory Commented Articles Epidemiology Articles

NAFLD progression rates: a real-world analysis

The aim of this study by R. Loomba et al. (NAFLD Research Center, University of California, San Diego, USA) was to evaluate the impact of disease severity, demographics and comorbidities on risk of mortality and time to progression in a large, real-world cohort of diagnosed NAFLD patients...

ByDr. D. Beard
OnMay 25, 2021

NASH Observatory Commented Articles

Patients with psoriasis: a screening algorithm for NAFLD

Psoriasis is an immune-mediated systemic inflammatory disease that may be associated with arthritis, cardiovascular diseases, metabolic syndrome including diabetes and obesity and as identified more recently, NAFLD, that occurs in approximately 50 % of all patients with psoriasis. In 2019, the American Academy of Dermatology...

ByDr. G. Bozet, MD
OnMay 20, 2021

NASH Observatory Commented Articles

Statin use among patients with NAFLD

Patients with NAFLD are at an increased risk of cardiovascular disease. Statins reduce the risk of cardiovascular events. Studies have shown statins are safe among patients with liver disease. Despite these data, statins are under prescribed among patients with liver disease due to concerns about hepatotoxicity. This study aimed to assess prevalence...

ByDr. D. Beard
OnMay 20, 2021

NASH Observatory Commented Articles Epidemiology Articles

Adult US population: NAFLD prevalence 38%, NASH 14%

S. A. Harrison et al. (Radcliffe Department of Medicine, University of Oxford, UK) prospectively assessed the prevalence and severity of NAFLD/NASH in a cohort of asymptomatic middle-aged Americans attending a colonoscopy class at a gastroenterology clinic. Screening for NAFLD was performed using magnetic resonance...

ByDr. G. Bozet, MD
OnMay 17, 2021

NASH Observatory Commented Articles Epidemiology Articles

Prevalence trends in NAFLD according to the Global Burden of Disease study

This study comprehensively investigated temporal trends in NAFLD prevalence at the global, regional, and national levels. The study included 21 regions and 195 countries or territories. The authors assessed secular trends in NAFLD risk factors, according...

ByDr. D. Beard
OnMay 17, 2021

Management Articles Commented Articles NASH Observatory Ppar Articles

Management of NAFLD: a review

As explained in the review by M. L. Petroni et al. (“Alma Mater” University, Bologna, Italy), several drugs are under investigation according to the agreed targets of reduced NASH activity without worsening of fibrosis or improving fibrosis without worsening of NASH.
Anti-inflammatory, anti-fibrotic agents and metabolism modulators...

ByDr. G. Bozet, MD
OnMay 10, 2021

NASH Observatory Commented Articles

Liver injury in COVID-19

The COVID-19 pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed a serious threat to global public health. Although primarily, the infection causes lung injury, liver enzyme abnormalities have also been reported to occur during the course of the disease. P. Anirvan et al. (Sriram Chandra Bhanj Medical College, Odisha, India) conducted...

ByDr. D. Beard
OnMay 10, 2021

Management Articles Commented Articles NASH Observatory

Comparative analysis of different guidelines

In their review, Y. Ando and J. H. Jou (Oregon Health & Science University Hospital, Portland, Oregon, USA) summaries updated guideline and guidance recommendations for the management of adult NAFLD. They highlight key difference between US, Asian, and European recommendations; and provide key updates...

ByDr. G. Bozet, MD
OnMay 5, 2021

Management Articles Commented Articles NASH Observatory

Is Europe ready to meet the challenge of fatty liver disease?

NAFLD is closely associated with obesity, metabolic syndrome, and diabetes. NAFLD can be optimally managed through a multidisciplinary patient-centred approach. National preparedness to address NAFLD is essential to allow for effective public health measures. NAFLD preparedness means having adequate policies and civil society...

ByDr. D. Beard
OnMay 5, 2021

NASH Observatory Commented Articles Epidemiology Articles

Changing trends of liver transplantation and mortality from NAFLD

This review by A. Majumdar (Australian National Liver Transplant Unit, Royal Prince Alfred Hospital, Sydney, and University of Sydney, Australia) and E. Tsochatzis (UCL Institute for Liver and Digestive Health, Royal Free Hospital and UCL, London, and Sheila Sherlock Liver Centre, Royal Free Hospital, London, UK) outlines the current epidemiology, natural history...

ByDr. G. Bozet, MD
OnMay 3, 2021